Vivani Medical, Inc. plans to initiate a Phase 1 clinical study for the NPM-139 semaglutide implant in the first half of 2026.
The company is also preparing for a Phase 2 clinical study of NPM-139 pending Phase 1 results and regulatory feedback.
NPM-139 aims to provide Wegovy®-level efficacy with once or twice-yearly administration for chronic weight management.
Clinical Development Plans
Phase 1 study for NPM-139 to start in the first half of 2026, with Phase 2 study to follow pending Phase 1 results and regulatory feedback.
Differentiation Potential
NPM-139 may offer improved tolerability and convenience compared to existing GLP-1 options, potentially capturing new market segments.
Therapeutic Potential
Positive preclinical weight loss data with NPM-139 indicates its potential to treat chronic diseases effectively with once or twice-yearly administration.
- The clinical program for NPM-139 focuses on evaluating safety, tolerability, and pharmacokinetics, with potential for significant differentiation in the competitive field of GLP-1 medications.
- Vivani aims to address unmet medical needs with NPM-139, leveraging its unique features to enhance patient adherence and minimize dosing fluctuations that lead to side effects.
Vivani Medical's innovative approach with the NPM-139 semaglutide implant shows promise in providing an effective and convenient solution for chronic weight management, potentially transforming treatment options in the field of GLP-1 medications.